TB Alliance CEO On Derailed Treatment In Ukraine, Pediatric Pretomanid Plans
Executive Summary
TB Alliance CEO Mel Spigelman discusses the huge disruptions in TB treatment in war-ravaged Ukraine, and need for funding, political will and resources along the lines of that galvanized for COVID-19, or "even a fraction" of that, to control the deadly infectious disease. He also touched on the accelerated availability of the BPaL regimen and a partnered program for an anti-TB natural product.
You may also be interested in...
WHO On Dire Need For Essential Medicines In Ukraine
As Russia continues its invasion of Ukraine by bombarding cities across the country, the World Health Organization and the UK government have issued updates on the medicines and other medical supplies they are donating to Ukraine, and the urgency of the situation on the ground.
TB Alliance CEO On Less Toxic Treatment Regimens, Pretomanid Plans
TB Alliance CEO Mel Spigelman discusses a range of new and evolving aspects pertaining to the three-drug BPaL regimen for highly drug-resistant TB, including the ZeNix trial results and adding a licensee for pretomanid. He also notes how COVID-19 has had a “terrible impact” on efforts to tackle the TB pandemic.
TB Vaccine Development: COVID-19 Pathways, mRNA Tech Hold Hope
With fast-tracked development and deployment of COVID-19 vaccines yielding results, experts call for similar urgency and funding impetus to progress new vaccines for TB, which still claims 4,000 lives daily. Over 15 candidates have been in development for years, with hope now abounding around the potential of new platforms like mRNA to accelerate efforts.